DBV Technologies S.A.
corporate_fare Company Profile
DBV Technologies S.A. (NASDAQ:DBVT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for DBVT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for DBVT spans 10-Q, 8-K, S-3ASR, PRE 14A.
Recent high-impact activity:
- DBV Technologies Flags Going Concern: $165.7M Cash, Runway Into Q3 2027
- DBV Submits BLA to FDA for VIASKIN Peanut Patch in Children 4-7, Requests Priority Review
- DBV Technologies Registers a New $150M At-the-Market Equity Program
- DBV Technologies Q2 2026: Cash Burn Accelerates, BLA Submission Delayed to Q3
- DBV Technologies Q2 2026: Cash Burn Accelerates as BLA Submission Slips to Q3
Financial Snapshot
Short Interest & Short Volume
1.67 days to coverFINRA reported short interest of 806,674 shares in DBVT as of the October 30, 2026 settlement, a 7.5% decrease from the prior period — about 1.7 days to cover at its recent average daily volume. On November 20, 2026, 68.1% of DBVT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for DBVT, detected from its recent SEC filings · based on capital-structure filings through 2026-07-27.
New $150M ATM Program Registered · Cash Burn Context
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →